Nhanho 3 Isiri Diki Sero Remapapu Kurapa Kenza: 2026 Kubudirira & Kupona Mareti 

Stage 3 isiri diki cell cancer kurapwa muna 2026 yakashanduka ikava nzira ine simba, ine multimodal inosanganisa immunotherapy, yakanangwa kurapa, uye nekuvhiya chaiko. Ikozvino mabudiro anotarisa kune neoadjuvant immune-checkpoint inhibitors kudzika mapundu asati avhiyiwa uye novel antibody-drug conjugates (ADCs) kune chaiwo genetic mutations. Huwandu hwekupona huri kuwedzera zvakanyanya, nezvidzidzo zvichangoburwa zvichiratidza kufambira mberi-pasina kupona kunopfuura mwedzi gumi neshanu kune varwere vanowana consolidation immunotherapy mushure mechemoradiation.

Kunzwisisa Danho 3 Isiri-Idiki Cell Lung Cancer muna 2026

Nhanho 3 isiri-diki yekenza yemapapu (NSCLC) inomiririra chiitiko chakakosha muoncology apo chirwere chapararira kune lymph nodes dziri pedyo asi kwete kunhengo dziri kure. Iyi nhanho inowanzotsanangurwa seyakafambira mberi munharaunda uye yakakura kwazvo, inoda nzira dzekurapa dzemunhu. Muna 2026, tsananguro yekurapika yakawedzera, nevarwere vazhinji vaimbonzi "vasingarambike" vava kukwikwidza mukuvhiya nechinangwa chekurapa nekuda kwekurapa kunoshanda.

Iyo yakaoma yeStage 3 NSCLC iri mukusiyana kwayo. Vamwe varwere varipo vane kushoma nodal kubatanidzwa kwakakodzera kuvhiyiwa nekukurumidza, nepo vamwe vane chirwere chakakura chinoda systemic therapy kutanga. Maitiro emazuva ano anoisa varwere mumapoka anogona kudzoreredzwa, anogona kudzokororwa, uye asina kuregererwa kuti agadzirise kutevedzana kwechemotherapy, radiation, immunotherapy, uye kupindira kwekuvhiya.

• Resectable: Mamota anogona kubviswa zvachose pakuvhiyiwa pakuongororwa.
• Zvinogona Kudzoserwa: Mabundu anogona kushanda mushure me neoadjuvant (pre-kuvhiya) kurapwa.
• Zvisingarambiki: Chirwere chepamusoro munharaunda umo kuvhiyiwa kusingagoneki; kurapwa ne-definitive chemoradiation inoteverwa ne-consolidation therapy.

Kunyatsoita dhizaini uchishandisa kufungidzira kwepamberi uye mamorekuru profiling ikozvino yave tsika yakajairika. Kuziva kuchinja kwemutyairi seEGFR, ALK, kana HER2 kwakakosha, sezvo ichiraira kana murwere achibatsirwa kubva kunangwa tyrosine kinase inhibitors (TKIs) kana antibody-drug conjugates pane yakajairika immunotherapy chete.

Kubudirira muNeoadjuvant uye Perioperative Therapy

Kunyanya kukosha kwekuchinja nhanho 3 isiri diki sero remapapu kurapwa mumakore maviri apfuura ndiko kutorwa kwakapararira kweneoadjuvant chemo-immunotherapy. Iri zano rinosanganisira kupa chemotherapy yakasanganiswa neimmune checkpoint inhibitors vasati vavhiyiwa. Chinangwa ndechekuzadzisa Pathological Complete Response (pCR), uko pasina masero emukenza anoshanda anowanikwa mumuenzaniso wekuvhiya, unoenderana zvakanyanya nekupona kwenguva refu.

Dhata yekiriniki yakaunzwa kumisangano mikuru yeoncology mukutanga kwa2026 inosimbisa kushanda kwePD-1 inhibitors mune ino marongero. Maagents akadai se sintilimab uye toripalimab vakaratidza mhedzisiro yakasimba mukuderera kwemamota uye kubvisa malymph nodes. Kune varwere vane squamous cell carcinoma, misanganiswa iyi yakaratidza kunyanya kupindurwa kwemazinga, zvichiita kuti mamwe maR0 resections (kubviswa kwakakwana nemiganhu isina kunaka).

Basa reMRD Monitoring

Iyo yekucheka-kumucheto budiriro muna 2026 ndiko kubatanidzwa kweMinimal Residual Disease (MRD) yekutarisa. Nekuongorora kutenderera bundu DNA (ctDNA) muropa mushure mekuvhiyiwa, oncologists vanogona kuona microscopic chirwere chinopotsa kufungidzira. Zvichangoburwa zvakawanda zvidzidzo zvinosanganisira adjuvant aumolertinib yeEGFR-mutant varwere vakashandisa MRD kutungamira nguva yekurapa. Kana MRD ikaramba isina kunaka, mamwe maprotocol anoratidza de-escalating therapy kuderedza chepfu, nepo MRD yakanaka ichikonzera kupindira kwakanyanya.

Iyi nzira chaiyo inovimbisa kuti varwere vanowana chaizvo huwandu hwekurapa hwavanoda. Inodzivirira kuwandisa kune avo vakatoporeswa nekuvhiyiwa uye inopa kurapa kwekutanga salvage kune avo vari panjodzi huru yekudzokazve. Iko kushandiswa kweMRD kuri kukurumidza kuve yakajairwa biomarker muzviyedzo zvekiriniki uye iri kukurudzira kuita kwepasirese-kuita sarudzo yeStage 3 manejimendi.

Definitive Chemoradiation uye Consolidation Immunotherapy

Kune varwere vane unresectable Stage 3 NSCLC, concurrent chemoradiation (cCRT) inoramba iri musana wekutarisira. Nekudaro, iyo post-radiation landscape yakashandurwa nekubatanidza immunotherapy. Iyo paradigm yakagadzwa neyekare PACIFIC yekuyedza data yakasimbiswa uye yakawedzerwa nevamiriri vatsva uye yakareba yekutevera data inowanikwa muna 2026.

Updates pamusoro Consolidation Strategies

Zvichangoburwa kubva muongororo yeCONSIST, yakapihwa kutanga kwa2026, inopa humbowo hunogutsa hwekushandiswa kwe sintilimab senzira yekubatanidza kurapa inotevera cCRT. Mune ino tarisiro, yakawanda yekudzidza, varwere vakawana kudzora kwechirwere mushure mechemoradiation vakagamuchira sintilimab kusvika kumwedzi makumi maviri nemana. Mhedzisiro yacho yakaratidza kufambira mberi-kusina kupona (PFS) kwemwedzi gumi neshanu, nemwedzi makumi maviri nemana ekupona kwese kunosvika 80%.

Izvi zvinosimbisa kuti PD-1 inhibitors inzira inoshanda uye ine simba kune PD-L1 inhibitors mukubatanidzwa kwekugadzirisa. Iyo yekuchengetedza mbiri yaigoneka, iine mwero wakaderera wezvakakomba zvine chekuita nemhomho. Iyi data inopa tariro kune varwere vangave vasingashiviriri mamwe ma immunotherapies kana kugara munzvimbo dzinowanikwa mishonga chaiyo.

• Chiyero Chekuchengetedza: Concurrent platinum-based chemotherapy uye radiation.
• Consolidation: Kutanga kwe immunotherapy mukati 1-6 mavhiki mushure meCCRT yapera.
• Nguva: Inowanzo kuenderera kwemwedzi 12 kusvika ku24 kana pasina kufambira mberi kunoitika.

Kusarudzwa kwemumiririri kunowanzoenderana nemvumo yedunhu uye nemurwere-zvakananga zvinhu. Kunyange zvazvo durvalumab yakaisa chiyero chekutanga, kupinda kwemukati uye kune dzimwe nyika PD-1 inhibitors yakagadzira nzvimbo yemakwikwi inobatsira varwere kuburikidza nekuwedzera kwekuwana uye nzira dzakasiyana dzekuita.

Targeted Therapies for Driver-Mutated Stage 3 NSCLC

A subset yeStage 3 NSCLC varwere vanobata chaiwo genetic driver, kunyanya EGFR mutations. Nhoroondo, varwere ava vaibatwa zvakafanana kune avo vasina shanduko, asi 2026 inocherekedza gore rekuparadzaniswa kwakasiyana munzira dzekurapa. Kushanda kweEGFR-Tyrosine Kinase Inhibitors (TKIs) mune adjuvant uye neoadjuvant marongero ikozvino yakanyatso kunyorwa.

Adjuvant EGFR-TKI Therapy

Dhata yakaburitswa mukutanga 2026 maererano ne aumolertinib uye osimertinib inosimbisa kukosha kwavo mukudzivirira kudzoka kwevarwere veEGFR-mutant. Zvidzidzo zvepasi rose kubva kuChina neEurope zvakaratidza kuti adjuvant TKI therapy inowedzera zvakanyanya kupona-kusununguka kwechirwere kana uchienzaniswa nechemotherapy chete. Kune Stage IA kune IIIA varwere vakawana resection yakakwana, oral TKIs vari kuwedzera kusarudzwa nekuda kweavo anofarirwa mhedzisiro profiles uye yakakwirira yekuteerera mitengo.

Uyezve, kutsvagisa kuri kuongorora basa reTKIs mune neoadjuvant marongero. Early-phase miedzo inoratidza kuti pfupi-kosi TKI kurapwa pamberi pekuvhiyiwa kunogona kunyatso kudzikisa mapundu muEGFR-positive varwere, kunyangwe kunyatsotarisisa nzira dzekuramba kuchidikanwa. Iyo network meta-kuongorora yakapihwa pamisangano ichangoburwa inotsigira hukuru hwechitatu-chizvarwa TKIs pamusoro pezvizvarwa zvakapfuura mune adjuvant mamiriro.

Zvinangwa zviri kubuda: HER2 uye KRAS

Kupfuura EGFR, zvimwe zvinangwa zviri kuwana traction. HER2 kuchinja, kunyangwe kushoma, kwave kuita nemvumo yetrastuzumab deruxtecan (T-DXd). Iyi antibody-drug conjugate yakaratidza kushanda kunoshamisa mune metastatic marongero uye iri kuferefetwa kune yekutanga-danho chirwere. Saizvozvo, KRAS G12C inhibitors senge elisrasib iri kuratidza vimbiso muChikamu 1/2 miedzo yeyakamborapwa yepamberi NSCLC, ichivhura mikova yekubatanidzwa mune ramangwana muStage 3 protocol.

Kuvhiya Kufambira mberi uye Multimodal Integration

Kuvhiya kunoramba kuri iko kwega mushonga wegomarara remapapu, uye basa rayo muStage 3 chirwere chiri kutsanangurwa patsva neari nani systemic kurapa. Pfungwa ye "kuvhiyiwa kwekushandura" iri pakati pe2026 kurapwa algorithms. Varwere vanotanga vauya nechirwere chisingachinjiki nekuda kwekubatanidzwa kwenodal kana kukura kwebundu vanogona kuvhiyiwa mushure memhinduro yakasimba kune neoadjuvant therapy.

Maitiro ekushandurwa kuvhiyiwa

Kusarudza nguva yekushanda mushure mekurapa neoadjuvant kunoda timu yemarudzi akawanda. Zvinhu zvakakosha zvinosanganisira kuwanda kwebundu shrinkage, kucheneswa kwema mediastinal lymph nodes, uye kuchengetwa kwemuviri wemurwere. Maitiro ekufungidzira epamberi, anosanganisira PET-CT uye MRI, anobatsira vanachiremba vanovhiya kuti vaongorore rectability nenzira kwayo kupfuura nakare kose.

Minimally invasive techniques, yakadai seVhidhiyo-Assisted Thoracoscopic Surgery (VATS) uye robotic-inobatsira kuvhiyiwa, iri kuwedzera kushandiswa kunyange mumatambudziko akaoma Stage 3. Idzi nzira dzinoderedza nguva yekudzorera uye dzinobvumira varwere kuti vatange adjuvant therapies nokukurumidza. Iko kubatanidzwa kweiyo intraoperative navigation masisitimu inowedzera kuwedzera kurongeka kweiyo lymph node dissection, kuve nechokwadi chekuita kwakaringana uye kutonga kwenzvimbo.

• Pre-operative Assessment: Re-staging mushure me neoadjuvant therapy kuratidza kuderera.
• Kuvhiya Nzira: Sarudzo yenzira shoma shoma kana zvichiita.
• Post-operative Care: Kurumidza kupora mapuroteni ekufambisa panguva yakakodzera adjuvant kurapwa.

Kubatana pakati pekurapa oncology uye kuvhiyiwa kwe thoracic hakuna kumbove kwakasimba. Hurukuro dzebundu bhodhi dzenguva dzose dzinoita kuti murwere wese weDanho rechitatu agamuchire hurongwa hwakarongeka hunowedzera mukana wekurapwa uku uchideredza kurwara.

Kuenzaniswa kweMarapirwo eMarapirwo eChikamu chechitatu NSCLC

Kusarudza nzira yekurapa yakakodzera kunoenderana nezvakawanda zvinhu zvinosanganisira rectability, chimiro chemolecular, uye maitiro ekuita. Tafura inotevera inofananidza nzira dzekutanga dziri kushandiswa muna 2026.

Kuenzanisa uku kunoratidza kuti hapana-saizi-inokodzera-yese mhinduro. Mafambiro aya ari kufamba akananga kumushonga wakasarudzika uko maitiro ebhayoloji ebundu anotyaira sarudzo yekurapa. Semuenzaniso, murwere ane EGFR mutation angangopfuura immunotherapy achifarira TKIs, nepo murwere ane yakakwira PD-L1 kutaura uye pasina shanduko angave wekutanga mumiriri we chemo-immunotherapy.

Kupona Mareti uye Prognostic Zvinhu muna 2026

Survival statistics ye nhanho 3 isiri diki sero remapapu kurapwa ari kunatsiridza, zvichiratidza kushanda kunoita marapiro matsva aya. Nepo nhoroondo dzekupona kwemakore mashanu dzakatenderedza 15-30%, data yemazuva ano inoratidza kuti nhamba idzi dziri kukwira, kunyanya kumapoka madiki anopindura zvakanaka kune immunotherapy.

Impact yeImmunotherapy paKurarama Kwenguva Yakareba

Kuunzwa kwekubatanidza immunotherapy kwakagadzira "muswe" pane inopona curve, zvichireva kuti subset yevarwere inowana kutonga kwenguva refu kwechirwere kwaimbove kushoma. Zvidzidzo zvinoratidza kuti varwere vanopedza kosi yakazara yekubatanidza kurapa uye vanoramba vasingafambire mberi pamakore maviri vane mukana wakakura kwazvo wekurarama kwenguva refu.

Saizvozvo, kubudirira kwepCR kunotevera neoadjuvant therapy ndiyo ine simba kufungidzira kwemhedzisiro. Varwere vanosvika pCR vanowanzoona zviitiko-pasina mazinga ekupona anopfuura 80% pamakore matatu. Izvi zvaita kuti pCR ive magumo ekupedzisira mumiyedzo yakawanda yekiriniki, ichimhanyisa kuvandudzwa kwemisanganiswa yemishonga mitsva.

Prognostic Variables

Zvinhu zvinoverengeka zvinokanganisa fungidziro yemunhu:

• Nodal Status: Nhamba uye nzvimbo inobatanidzwa lymph nodes (N1 vs. N2 vs. N3) inoramba ichinyanya kukosha.
• Molecular Profile: Kuvepo kweanogona kuita shanduko kunowanzo kupa mhedzisiro iri nani neanonangwa marapirwo.
• Performance Status: Varwere vane chimiro chakanaka chekushanda vanoshivirira aggressive multimodal therapy zviri nani.
• Mhinduro kune Induction: Iyo dhigirii yebundu shrinkage mushure mekutanga kurapwa inofanotaura kubudirira kwekuvhiya uye kupona.

Zvakakosha kuziva kuti mararamiro ekupona maavhareji. Mhedzisiro yega yega inosiyana zvakanyanya zvichienderana nemusanganiswa chaiwo wekurapwa kwakagamuchirwa uye maitiro ebhayoloji egomarara. Chinangwa chemazuva ano oncology ndechekushandura murwere wese muchikamu chakanaka chekufungidzira kuburikidza nekupindira chaiko.

Kugadzirisa Side Effects uye Hunhu hweHupenyu

Kurapa zvine hukasha kweStage 3 NSCLC kunouya nenjodzi dzehupfu. Kugadzirisa izvi mhedzisiro kwakakosha kuchengetedza dosi kusimba uye hupenyu hwehupenyu. Iwo eparutivi maitiro profiles anosiyana zvakanyanya pakati pechemotherapy, radiation, immunotherapy, uye vamiririri vanonangwa.

Zviitiko Zvakaipa Zvinoenderana Nekudzivirira Kwemuviri (irAEs)

Immunotherapy inogona kukonzera kuzvimba mumitezo ine hutano, inozivikanwa seIrAEs. Zvinowanzoitika zvinosanganisira pneumonitis, colitis, dermatitis, uye endocrine kusagadzikana senge hypothyroidism. Muchidzidzo cheCONSIST, pneumonitis yainyanya kunetseka, ichiitika munenge 23% yevarwere, kunyangwe zviitiko zvakakomba zvaive zvisingawanzo. Kuonekwa kwekutanga uye kutonga ne corticosteroids kwakakosha.

Varwere vanowana consolidation immunotherapy mushure memwaranzi vari panjodzi yakanyanya yepulmonary toxicity. Yepedyo yekutarisa neyakajairwa CT scans uye chiratidzo cheki ndiyo yakajairwa protocol. MaIRAE mazhinji anodzoserwa kana akabatwa nekukurumidza, achibvumira varwere kuti vaenderere mberi kana kutangazve kurapwa zvakachengeteka.

Toxicity kubva kuTargeted Therapies

EGFR-TKIs inowanzova neakasiyana toxicity profile, inoratidzirwa nekuputika kweganda, manyoka, uye dzimwe nguva interstitial chirwere chemapapu. Kunyange zvichiwanzo kushivirira kupfuura chemotherapy, kutonga kusingaperi kunoda kusvinura. Zvizvarwa zvitsva zveTKIs zvakanatsiridza miganho yekuchengetedza, asi kutarisa kwemoyo uye bvunzo dzeophthalmologic dzinogona kukurudzirwa zvichienderana nemumiriri chaiwo.

• Chemotherapy: Nausea, kuneta, neutropenia.
• Radiation: Esophagitis, maitiro eganda, kuneta.
• Immunotherapy: Autoimmune reactions inokanganisa mapapu, ura, ganda, kana mahomoni.
• Targeted Therapy: Rash, manyoka, chaiwo nhengo toxicities.

Mapoka ekuchengeta anotsigira anoita basa rakakosha mukugadzirisa zviratidzo izvi. Rutsigiro rwekudya kunovaka muviri, kurapa kwemuviri, uye kuraira kwepfungwa zvikamu zvakakosha zverwendo rwekurapa, kubatsira varwere kuchengetedza simba uye tsika muhurongwa hwese hwakasimba.

Ramangwana Mamiriro: Emerging Trends uye Clinical Miedzo

Munda we nhanho 3 isiri diki sero remapapu kurapwa iri kukurumidza kushanduka, iine miedzo yakawanda yekiriniki yakagadzirira kutsanangura patsva mipimo mumakore anotevera. Tarisiro iri kuchinjika yakananga kudoublet immunotherapy, novel ADCs, uye yakanatswa kusarudzwa kwemurwere uchishandisa mvura biopsies.

Next-Generation Antibody-Drug Conjugates

ADCs ari kuwedzera kupfuura HER2. Zvivakwa zvitsva zvinonangana neTROP2, B7-H3, uye mamwe maantigen ari mukuvandudzwa. Mishonga iyi inopa mukana wekuendesa chemotherapy ine simba zvakananga kumaseru egomarara uku uchichengetedza matishu akajairwa. Yekutanga data mune metastatic marongero ari kuvimbisa, uye miedzo yave kuvhurika yepakutanga-danho chirwere, kusanganisira Stage 3.

Semuyenzaniso, vamiririri vakaita seYL202/BNT326 (a HER3 ADC) vari kuongororwa muyedzo yeChikamu chechipiri cheNSCLC. Kana zvikabudirira, izvi zvinogona kupa sarudzo kune varwere vasingapindure kune yazvino immunotherapies kana vamiririri vakanangwa. Iko kuita kwakasiyana-siyana kweADCs kunoita kuti ive dombo repakona remangwana ekubatanidza mazano.

Majekiseni Akasarudzika uye Mishonga Yeserura

Messenger RNA (mRNA) vajekiseni yegomarara yakarongedzerwa kuchinjika kwechirwere chemurwere vari kupinda mumiedzo yekupedzisira. Kana yakasanganiswa necheckpoint inhibitors, aya majekiseni anovavarira kukurudzira yakasimba uye yakananga mhinduro yekudzivirira. Pamusoro pezvo, kurapwa kwesero senge TILs (Tumor-Infiltrating Lymphocytes) iri kuongororwa mabundu akasimba, ichipa nzira inogona kuita refractory kesi.

Kubatanidzwa kwehungwaru hwekugadzira mukuronga kurapwa kuri kuwedzerawo. AI algorithms inogona kuongorora yakakura dhataseti yekufungidzira, genomics, uye mhedzisiro yekiriniki yekufungidzira yakanakisa kurapwa kutevedzana kune mumwe nemumwe murwere. Iyi nhanho yekusarudzika inovimbisa kuwedzera kushanda uku uchideredza hupfu husina basa.

Mibvunzo Inowanzo bvunzwa Nezve Stage 3 NSCLC Kurapa

Varwere nemhuri vanowanzova nemibvunzo yakawanda kana vatarisana neStage 3 kuongororwa. Hedzino mhinduro dzemimwe mibvunzo yakajairika yakavakirwa pazvino kubvumirana kwekurapa 2026.

Nhanho 3 Kenza Yemapapu Inorapika Here?

Ehe, Stage 3 NSCLC inogona kurapika, kunyanya neazvino multimodal marapirwo. Tsanangudzo ye "kurapa" inowanzoreva kuramba usina chirwere kwemakore mashanu kana kupfuura. Nekuuya kweneoadjuvant immunotherapy uye yakagadziridzwa maitiro ekuvhiya, nhamba yevarwere vanowana kuregererwa kwenguva refu iri kuwedzera.

Kurapa Kunotora Nguva Yakadii?

Nguva yekurapa inosiyana. Neoadjuvant therapy inowanzotora 3-4 cycles (inenge 2-3 mwedzi), inoteverwa nekuvhiyiwa uye kupora. Adjuvant kana consolidation marapiro anogona kuenderera kusvika makore 1-2. Mishonga yakanangwa inogona kutorwa nemuromo kwemakore akati wandei zvichienderana nekushivirira uye chimiro chechirwere.

Chii Chinoitika Kana Cancer Ikadzoka?

Kana kudzokorora kukaitika, nzira dzekurapa dzinoenderana nenzvimbo uye chiyero chekudzoka. Zvinoitika zvekare zvinogona kurapwa nekuvhiyiwa kana nemwaranzi kana zvisina kushandiswa kare. Metastases ari kure anowanzo gadziriswa ne systemic therapies, kusanganisira yechipiri-mutsara immunotherapies, inotarirwa vamiririri, kana kiriniki miedzo. Kuvepo kwemakirasi emishonga akasiyana zvinoreva kuti pane dzinenge nguva dzose dzinotevera mitsara yekurapa yekuongorora.

• Kuongorora: Kugara uchitevera kushanya uye ma scan kwakakosha pakuona nekukurumidza kwekudzoka.
• Yechipiri-Mutsetse Sarudzo: Sanganisira makirasi akasiyana emishonga asina kushandiswa mukutanga.
• Miedzo yekiriniki: Kazhinji kupa mukana wekurapa-kumucheto kurapwa kusati kwave kuwanikwa zvakanyanya.

Mhedziso: Nguva Itsva yeTariro uye Nechokwadi

The landscape ye nhanho 3 isiri diki sero remapapu kurapwa muna 2026 inotsanangurwa netarisiro uye nemazvo. Shanduko kubva kune imwe-saizi-inokodzera-yese nzira kuenda kune yakasarudzika yakasarudzika yakaunza budiriro inobatika mukupona uye kunaka kwehupenyu. Kubva pakushandiswa kwakapararira kweneoadjuvant immunotherapy kusvika pakunatswa kwekutarisirwa kweadjuvant, varwere vane maturusi akawanda kupfuura nakare kose kurwisa chirwere ichi.

Zvinotora zvakakosha zvevarwere nevapeji zvinosanganisira kukosha kwekuyedzwa kwemamorekuru, kukosha kwemabhodhi emhando dzakasiyana-siyana dzebundu, uye kukosha kwekuomerera pakurapa kwekubatanidza. Sezvo tsvagiridzo ichienderera mberi nekuvhura zvibodzwa zvitsva zvibodzwa uye kunatsa maprotocol aripo, iyo trajectory yeStage 3 NSCLC inonongedza kumusoro. Kudyidzana pakati penharaunda dzepasi rose dzekutsvagisa, kunoratidzwa nekugovana data pamisangano yakaita seELCC neASCO, kunovimbisa kuti mabudiro aya anosvika kuvarwere nekukurumidza.

Kunyange zvipingamupinyi zvichiripo, kunyanya mukugadzirisa chepfu uye kuwana rubatsiro pasi rose, kufambira mberi kwakaitwa mumakore mashoma apfuura hakurambike. Kune ani nani ari kufamba neStage 3 kuongororwa nhasi, meseji iri pachena: kune anoshanda, anotsigirwa nesainzi nzira dzekupona kwenguva refu, uye ramangwana rine vimbiso yakatokura.